Status:
UNKNOWN
RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique
Collaborating Sponsors:
Amgen
Conditions:
Nsclc
KRAS P.G12C
Eligibility:
All Genders
18-90 years
Brief Summary
The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the...
Detailed Description
The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU applications in order to collect retrospectively, as soon as possible after inclusion and under real-life conditions, the...
Eligibility Criteria
Inclusion
- Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib
- Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co mutations allowed)
- Patients who received at least one dose of the treatment with sotorasib as part of the French Early Access Program (ATU program)
- Patients who were informed about the study and do not object for their data to be collected
- Age \> 18 years
Exclusion
- Patients enrolled in a sotorasib clinical trial
- Patients with a psychiatric history that hinders the comprehension of the information leaflet
- Patients under curatorship or guardianship
- Unable to obtain data collection
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
458 Patients enrolled
Trial Details
Trial ID
NCT05273047
Start Date
March 1 2022
End Date
December 31 2024
Last Update
September 29 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Paris - Hôpital Cochin
Paris, France
2
Rouen - CHU
Rouen, France
3
Strasbourg - CHU
Strasbourg, France